Kit Check Brings Next-Generation Medication Tracking Mainstream with FDA Pilot
Summary
The program, which includes efforts from Hackensack University Medical Center, Coral Gables Hospital, Nephron Pharmaceuticals and Sandoz, a Novartis division. “Since the implementation of DSCSA in 2015, the FDA has made impressive strides to improve the safety and security of the drug supply chain,” said Lou Kennedy, chief executive officer, Nephron. The labels and markers will be included on a range of injectable drugs in vials and pre-filled syringes that meet the definitions laid out by the FDA – following their journey from manufacturing through the hospital. Upon conclusion, the FDA will make the final reports public alongside other DSCSA 2023 participants’ findings, with the hope that all supply chain stakeholders can benefit from the data. Our solutions blend powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes and help hospital pharmacies cut costs, reduce risk, and get more done.